Trade OpGen, Inc. - OPGN CFD
Add to favourite- Summary
- Historical Data
Spread | 0.07 | ||||||||
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023374% | ||||||||
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001151% | ||||||||
Overnight fee time | 22:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5.00% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
Prev. Close | N/A |
Open | 2.27 |
1-Year Change | 453.66% |
Day's Range | 1.88 - 2.73 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Aug 19, 2024 | 1.93 | -0.33 | -14.60% | 2.26 | 2.83 | 1.85 |
Aug 16, 2024 | 2.28 | 0.05 | 2.24% | 2.23 | 2.29 | 2.22 |
Aug 15, 2024 | 2.23 | 0.04 | 1.83% | 2.19 | 2.24 | 2.19 |
Aug 14, 2024 | 2.20 | 0.01 | 0.46% | 2.19 | 2.27 | 2.11 |
Aug 13, 2024 | 2.08 | -0.15 | -6.73% | 2.23 | 2.23 | 2.05 |
Aug 12, 2024 | 2.09 | -0.11 | -5.00% | 2.20 | 2.20 | 2.05 |
Aug 9, 2024 | 2.22 | 0.00 | 0.00% | 2.22 | 2.22 | 2.21 |
Aug 8, 2024 | 2.27 | 0.04 | 1.79% | 2.23 | 2.27 | 2.23 |
Aug 7, 2024 | 2.28 | 0.04 | 1.79% | 2.24 | 2.32 | 2.16 |
Aug 6, 2024 | 2.24 | -0.09 | -3.86% | 2.33 | 2.50 | 2.24 |
Aug 5, 2024 | 2.48 | -0.10 | -3.88% | 2.58 | 2.61 | 2.16 |
Aug 2, 2024 | 2.72 | -0.11 | -3.89% | 2.83 | 2.87 | 2.71 |
Aug 1, 2024 | 2.93 | 0.00 | 0.00% | 2.93 | 2.96 | 2.86 |
Jul 31, 2024 | 2.87 | -0.04 | -1.37% | 2.91 | 2.94 | 2.85 |
Jul 30, 2024 | 2.94 | -0.02 | -0.68% | 2.96 | 3.00 | 2.94 |
Jul 29, 2024 | 2.98 | -0.06 | -1.97% | 3.04 | 3.04 | 2.96 |
Jul 26, 2024 | 2.99 | 0.03 | 1.01% | 2.96 | 3.02 | 2.96 |
Jul 25, 2024 | 2.97 | 0.01 | 0.34% | 2.96 | 3.04 | 2.96 |
Jul 24, 2024 | 2.96 | 0.02 | 0.68% | 2.94 | 2.96 | 2.94 |
Jul 23, 2024 | 2.98 | -0.02 | -0.67% | 3.00 | 3.00 | 2.90 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
OpGen, Inc. Company profile
OpGen, Inc., a precision medicine company, engages in developing molecular information products and services in the United States and internationally. The company utilizes molecular diagnostics and informatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections, enhance patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms. The company''s products include Acuitas AMR Gene Panel, a vitro diagnostic test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen; and QuickFISH and PNA FISH diagnostic test products for the identification of various infectious pathogens, as well as SARS CoV-2 test kits. In addition, it offers Acuitas Lighthouse informatics systems, a cloud-based HIPAA compliant informatics, which combines clinical lab test results with patient and hospital information to provide analytics and insights to enable manage MDROs in the hospital and patient care environment; Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers; and ARES Technology Platform, including ARESdb, which provides next generation sequencing based and artificial intelligence powered, cloud-based bioinformatics solutions to generate AMR profiles, as well as predict antimicrobial susceptibility test results. OpGen, Inc. has a strategic collaboration with the New York State Department of Health to develop a solution to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is based in Rockville, Maryland.Industry: | Biotechnology & Medical Research (NEC) |
9717 Key West Avenue
Suite 100
20850
News
Pi Network coin price prediction: Third party price target
Discover the Pi Network coin price predictions for 2025 onward, with analyst outlooks, price targets and CFDs trading strategies on Capital.com
13:51, 13 December 2024Euro forecast: third party data roundup
In 2024, the euro’s outlook appeared more stable. Read on for our 2025 and beyond insights.
22:39, 12 December 2024Projected US interest rates in 5 years: Third party round up
As the US central bank starts its cutting cycle, what are the projected interest rates in 5 years?
14:28, 12 December 2024Projected UK interest rates in 5 years
Bank of England (BoE) cut rates for the first time in August 2024, with further easing expected in the coming months. But how low are rates likely to go?
11:20, 12 December 2024Dogecoin (DOGE) price prediction 2025-2030: Could Dogecoin reach $1? - Third party price target
We look at the meme coin’s price performance and the latest DOGE price predictions
08:37, 12 December 2024Gold price predictions for the next five years: Third party data round up
Explore the future of gold prices and whether the yellow metal will continue its upward trend in the coming years.
09:13, 6 December 2024Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
12:47, 5 December 2024People also watch
Still looking for a broker you can trust?
Join the 660,000+ traders worldwide that chose to trade with Capital.com